Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +55

Intuitive Surgical (ISRG) Stock Fair Value Edges Higher After Mixed Q3 Analyst Revisions

Analyst upgrade Company update AI-generated analysis

πŸ“ˆ Intuitive Surgical's fair value estimate increased from US$476.34 to roughly US$486.57 per share following a mixed but net-positive analyst revision cycle.

πŸš€ Major firms including BofA, Barclays, JPMorgan, and Leerink lifted price targets citing strong Q3 system placements and confidence in procedure growth over time.

🌍 RBC and Barclays highlight robust da Vinci 5 system placements and steady procedure trends outside the U.S. as key supports for the company's growth runway.

πŸ’° Wells Fargo reported Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both exceeding analyst consensus expectations.

βš–οΈ Management's quantified 2027 pricing actions on instruments are viewed as a strategy to support adoption while keeping overall revenue per procedure impact in check.

πŸ“‰ Multiple analysts flag slowing U.S. procedure growth and policy-related volume pressures as key risks, particularly with high investor expectations already priced in.

πŸ“Š The annual revenue growth assumption was revised down from 11.93% to 11.74%, reflecting a more conservative long-term outlook.

πŸ’Έ Net profit margin expectations decreased from 30.72% to 29.76% as analysts adjust for potential margin compression in the sector.

πŸ“‰ The future P/E multiple expectation was lowered from 43.52x to 40.75x, suggesting a shift in valuation multiples despite the higher price target.

⚠️ Risks include new soft tissue robotic competitors, remanufactured instruments, and budget pressures in markets like China and parts of Europe.

Bullish Signals
  • Major analysts including BofA, Barclays, JPMorgan, and Leerink lifted price targets citing solid Q3 results and strong system placement strength.
  • RBC and Barclays highlight robust da Vinci 5 system placements and steady procedure growth trends outside the U.S. as key supports for future expansion.
  • Wells Fargo noted Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both beating consensus expectations.
  • Leerink points to capital demand and a focus on net new system growth in ambulatory surgery centers as key supports for the company's growth runway.
Risk Factors
  • Multiple analysts flag slowing U.S. procedure growth and sluggish procedures as a key concern, especially with high investor expectations already reflected in the stock.
  • Mizuho cites ongoing procedure headwinds and policy-related volume pressures that could weigh on near-term performance.
  • BofA and BTIG reference the risk that the sector may see a pause until investors gain confidence that lower 2027 estimates are achievable.
  • The annual revenue growth assumption was revised down from 11.93% to 11.74%, indicating a moderation in expected expansion rates.
  • Net profit margin expectations were lowered from 30.72% to 29.76%, suggesting potential pressure on profitability margins.
Full Analysis
Intuitive Surgical (ISRG) sees its fair value estimate rise from approximately US$476.34 to roughly US$486.57 per share, driven by a mixed but ultimately bullish analyst narrative following Q3 results. Major financial institutions including BofA, Barclays, JPMorgan, and Leerink have lifted their price targets, citing robust system placements for the da Vinci 5 platform and strong procedure growth trends outside the United States as key drivers of future revenue. Despite the positive fair value adjustment, analysts highlight specific headwinds that temper expectations. Wells Fargo notes Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both beating consensus, but warns that management's quantified pricing actions for 2027 instruments are intended to support adoption while potentially capping overall revenue per procedure impact. Several firms, including RBC and Mizuho, flag slowing U.S. procedure growth and policy-related volume pressures as significant concerns. Valuation assumptions have shifted slightly downward alongside the price target increase, reflecting a more cautious outlook on long-term margins and multiples. The annual revenue growth assumption has decreased from 11.93% to 11.74%, while the net profit margin expectation moved down from 30.72% to 29.76%. Additionally, the future P/E multiple was revised lower from 43.52x to 40.75x, indicating that while the stock price is expected to rise, the market is pricing in slightly slower growth and tighter profitability over the coming years.